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LITERATURE REVIEW
Introduction
Most swine produced for market in the United States are
raised in large, intensively managed, total confinement
operations. Farrow to finish operations with hundreds to
thousands of sows are common. Because large numbers of
animals are being closely confined, disease is always a major
concern. An outbreak of an acute infectious disease could
have disastrous consequences under these conditions,
consequently herd health and disease prevention have become
keys to the producer's success. Because disease is often the
culmination of many factors, an effective herd health program
must be multifaceted. Environment, nutrition, genetics,
infectious disease, and parasitism must all be managed in an
integrated fashion to maintain a successful operation. Many
factors influence the immune system and hence the animals
susceptibility to disease. Several recent reviews have
discussed the effects of various stressors on the immune
system. 1 " 4 Herd health programs work primarily to minimize
stressors on the immune system, alternatively a current area
of intense research is the search for exogenous substances
that can mitigate suppressive influences on the immune
system, or perhaps, even boost the immunological status of
the animal. These types of drugs are often referred to as
immunomodulators: broadly interpreted to refer to any drug
that influences the immune system, either enhancing or
suppressing, but commonly used to refer only to those
substances that potentiate immune responses- the definition
used in this thesis.
Immunomodulation
Immunomodulation may someday become a routine part of
production management in the swine industry. The growing
concern by consumers over the use of antibiotics as feed
additives may make immunomodulators a wise marketing choice
for pork producers. 5 Immunomodulators may also prove very
beneficial if they could be administered to mitigate
anticipated problem times in the production life of an
animal: e.g. weaning, transport, the neonatal period, during
disease outbreaks (especially viral disease), and during
inclement weather. Immunomodulators may also become valuable
in the treatment of several clinical syndromes where an
acquired immunodeficiency may be the underlying problem. This
literature review will briefly discuss some immunomodulators
that have been examined in swine.
Dietary Factors
Producers have realized the effects of diet on the
efficiency of production by food animals for quite some time,
however, recent investigations have revealed an influence of
diet on the immune system. Normal dietary constituents have
been shown to have an effect on the immune response. Not
suprisingly, amino acid supplementation in gestating sows fed
a low protein diet has been shown to increase antibody
production to sheep red blood cells, as well as increase
transfer of passive immunity to piglets. 6 Vitamin E and
selenium have also been investigated for their effect on the
immune system. Ellis and Vorheis demonstrated an increase in
whole cell agglutinin responses to an Escherichia coli whole
cell bacterin in animals fed supplemental vitamin E."7
Subsequently, Peplowski, et.al., showed increased antibody
titers to sheep red blood cells in weanling swine associated
with either feeding or injecting vitamin E or selenium with
an additive effect when both were administered. 8 In a similar
manner proliferative responses to phytohemagglutinin, a T
cell mitogen, were found to be augmented by feeding either
vitamin E or selenium, or both. 9 There is some evidence that
vitamin C may also be an effective immunomodulator in some
species. Roth and Kaberle reported enhanced neutrophil
functions when vitamin C was injected into cattle, 10 but
recent reports on the use of vitamin C in swine have shown no
effect on humoral or cellular immune responses. 11 - 12 We are
just now beginning to understand the profound effects diet
has on health, certainly more information will come to light
in this field in the future.
Cytokines
The understanding of the role of cytokines in the
regulation of the immune system combined with recombinant DNA
technology is opening an exciting area of potential
immunomodulators. Interferons are just one of the cytokines
under investigation as a possible immunomodulator of clinical
significance. Interferons are part of the hosts nonspecific
immune response to viral invaders; these cytokines,
synthesized by virally infected host cells, act to produce an
interferon-induced antiviral state that prevents viral
replication in the induced cell. 13 A recent study sought to
determine if bovine recombinant a-1 interferon (BoIFN) could
protect newborn pigs against transmissible gastroenteritis
virus (TGE) infection. Initial in vitro work showed that
BoIFN was effective in inhibiting replication of both
vesicular stomatitis virus and TGE virus in cultures of swine
testicular cells. However, when newborn pigs were
administered BoIFN orally at 12 hour intervals from 6 hours
of age and subsequently challenged with TGE, disease and
mortality were similar for both control and BoIFN treated
animals. Further data indicated that the BoIFN was
inactivated within one minute of entering the small
intestine; the authors concluded that BoIFN might be
effective in preventing TGE infection if a method could be
found to prevent enzymatic degradation in the small
intestine
.
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Interleukin-2 (IL-2) is another cytokine that through
recombinant DNA technology has become available in large
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enough quantities to allow clinical trials. This lymphokine,
secreted by T cells, is capable of stimulating T cell clonal
expansion, activation of cytotoxic T cells, and induction of
natural killer cell activity. 15 Pigs administered human
recombinant IL-2 and a Haemophilus pleuropneumoniae vaccine
had higher antibody titers to H. pleuropneumoniae and a lower
incidence of lung lesions after challenge. 16 - 1
"7 Interleukin-2
administration was also shown to increase natural cytotoxicity
in pigs when administered in vivo. 18 In a vaccination and
challenge experiment calves that recieved bovine recombinant
IL-2 had increased antibody titers, increased cytotoxic
responses, and decreased clinical disease; however, there
were significant clinical side effects associated with IL-2
administration. 19 These experiments indicate that there are
some exciting possibilities for the future use of IL-2, yet
more work must be done before this lymphokine is useful in a
clinical setting.
Levamisole
Levamisole was the first in a new class of
immunomodulators to be described. Originally marketed as an
anthelmintic drug, levamisole came under intense scrutiny
after a 1971 report that described an enhanced response by
mice to a Brucella vaccine when given levamisole. 20
Levamisole quickly became perhaps the most widely tested
immunoactive drug. The extensive literature about levamisole
has been well reviewed. 21-23 Our laboratory has reported some
work that demonstrated levamisole to be an effective
immunomodulator in artificially reared pigs. Pigs were
removed from the sow within two days of parturition and
artifically reared for 21 days. Levamisole and isoprinosine,
another immunomodulator discussed below, were administered to
separate groups of artificially reared pigs. Lymphocyte
proliferation and phytohemagglutinin skin responses were
evaluated in drug treated groups, artificially reared pigs,
and sow reared controls. Those pigs that were artificially
reared had decreased responses when compared to pigs that
remained with the sow. Both levamisole and isoprinosine were
effective in returning the immunologic parameters of
artificially reared pigs to sow reared control levels. 24 Other
workers demonstrated an increased secondary antibody response
to antigen after levamisole treatment. 25 Clearly, levamisole
can alter immune responses in mammals; but generally this drug
is only effective in enhancing suppressed immune systems. The
drug works primarily on phagocytes and T lymphocytes, with no
direct action on B cells. The exact mode of action of
levamisole remains unclear. The timing and dosage of the drug
appear to be very important in enhancing the immune response.
No alteration or actual suppression has been observed as a
consequence of levamisole administration. 21 " 23 A recent
review in a clinical journal outlined some guidelines for the
clinical use of levamisole. The authors suggested that
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levamisole only be used in immunosuppressed individuals at the
recommended dosage regimen, and only be used where immune
parameters could be monitored for improvement or adverse
reactions. In addition some of the problems associated with
the use of levamisole were outlined. The effects of the drug
appear to be inconsistant , nonresponsive individuals appear to
be present in most populations; increased inflammation and
gingivitis have been observed as adverse side effects. The
most severe side effect noted after levamisole administration
is the development of an autoimmune like reaction that results
in a severe agranulocytosis. 22 Unfortunatly, levamisole has
suffered from faddish popularity; a fact which Renoux
commented on in a 1978 review, advice that probably should be
applied to all new drugs in this field. "The random and
uncritical use of levamisole may produce inconsistent,
uninterpretable results and unjustifiably dampen the
enthusiasm for a rational, scientifically-based
immunopharmacology in the future." 26
Imuthiol
The ambivalent responses to levamisole led the Renoux
team to search for a compound devoid of the inhibitory effects
of levamisole, (thought to be due to cholinergic properties of
the imadazole moity) while retaining the positive aspects of
its immunomodulation ability. Sodium diethyldithiocarbamate
(also known as DTC and imuthiol) was the compound finally
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selected that fit the desired criteria. Imuthiol is a
chelating agent used in chemistry, agriculture, and in the
treatment of nickel poisoning. 2-7 This drug is nonmutagenic,
noncarcinogenic, nonpyrogenic , and nonantigenic. 28 Like its
predecessor imuthiol was found to act primarily on T-cells.
The compound is not active in vitro, but becomes an effective
immunoenhancer when administered in vivo. Imuthiol posseses
direct antibiotic effects, is protective against the effects
of ionizing radiation and can act as a detoxifier of chemicals
such as chloroform, carbon tetrachloride, and bromobenzene
.
Unlike levamisole, imuthiol appears to be effective over a
wide dose range without any deleterious side effects. B cells
are unaffected by imuthiol, however the drug has been shown to
speed the shift from IgM to IgG production, a T cell mediated
event. 27 - 29 Differentiation of T cell precursors, increased
natural killer cell activity, increased lymphocyte
proliferation to mitogens, and increased IL-2 production have
all been shown after in vivo imuthiol administration. 30-34
Imuthiol has been used in several laboratory animals and
humans. Individuals regained age suppressed T cell responses
after imuthiol administration. 30 Offspring of female mice
that received imuthiol during pregnancy had enhanced T cell
responses and neonatal growth rates. 35 - 3e Because of the
above observations we sought to evaluate the use of imuthiol
in the weanling pig. Pigs at weaning have decreased T cell
responses 37 and are often afflicted with disease, thereby
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making them good candidates for immunotherapy. The experiment
is fully described in the second part of this thesis.
Unfortunately, imuthiol was not effective in weaned pigs at
the dosage rates used. Perhaps, further experimentation will
illucidate an effective treatment regimen for imuthiol use in
the pig.
Isoprinosine
First investigated in 1972 as an antiviral drug by
Gordon and Brown, 38 isoprinosine was soon recognized as an
immunoenhancing drug. 39 Isoprinosine, a compound formed from
a 1:3 molar ratio of inosine and N,N-dimethylamino-2-propanol
,
is thought to affect purine metabolism, either by providing
substrate or perhaps through competetive inhibition of
enzymes, in such a way as to increase intracellular cGMP,
thereby stimulating T cells and macrophages. 40 Isoprinosine
has been shown to augment a number of T cell mediated
functions: increased lymphocyte blastogenesis , increased
cytotoxic T lymphocyte activity, increased IL-2 production, as
well as increased natural killer cell and macrophage
activity. 41 - 42 Clinically, isoprinosine has been shown to be
efficacious in treating human herpesvirus and chronic lung
infections. Positive clinical results have also been reported
in a number of other disease states. 41 - 42 Our laboratory
previously reported that isoprinosine successfully abrogated
the suppressive effect of artificial rearing in neonatal
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pigs. However, in a more recent experiment, described in
part III of this thesis, isoprinosine had no effect on
pseudorabies virus induced immunosuppression in feeder pigs.
Perhaps, the mode of immunoenhancement associated with
isoprinosine is able to compensate for the suppression caused
by management stressors (i.e. artificial rearing) but is not
able to reverse viral induced suppression.
Conclusions
Immunomodulators are not yet the silver bullet of
medicine, now or maybe ever. Yet, the new drugs offer new
ways to study, explore, and understand the immune system. A
better understanding of the regulation and action of the
immune system during normal and disease states should lead to
improved disease management and intervention regimens.
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SUMMARY
Mitogen-stimulated lymphocyte proliferation, delayed-type
hypersensitivity (DTH) reactions, interleukin-2 (IL-2)
production, and growth performance were evaluated in 3 -week-
old pigs treated with imuthiol. Lymphocyte proliferative
responses to Con A and PWM were reduced (P<0.05) in pigs
treated with imuthiol at 25 mg/kg; PHA proliferative responses
were not influenced by imuthiol treatment. Imuthiol at 2.5
mg/kg and 25 mg/kg lowered IL-2 production when compared to
saline-treated controls. Delayed-type hypersensitivity
responses to PHA were higher in 25 mg/kg imuthiol-treated
pigs; however, 2.5 mg/kg imuthiol-treated pigs had lower DTH
reactions. Imuthiol at 2.5 mg/kg and 25 mg/kg reduced
(P<0.05) average daily feed intake. These data suggest that
in vivo imuthiol treatment in pigs lowers lymphocyte
proliferative responses, IL-2 production, and growth
performance
.
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Introduction
Immunotherapeutic agents have been evaluated in cattle and
pigs as a means of stimulating nonspecific, natural
immunity. 1-3 Pigs that are weaned at an early age are more
affected than older animals by the stress of weaning and,
subsequently, are more susceptible to several disease
syndromes. s - 7 Thus, early weaned pigs could potentially
benefit from biologic response modifier immunoenhancement
.
Immunoenhancement at this critical time for the young pig
would most likely be reflected in decreased morbidity and
mortality, with concomitant financial gains for the producer.
One immunotherapeutic agent that has been shown to be
immunostimulatory in mammals is sodium diethyldithiocarbamate
( imuthiol)
.
Imuthiol has a marked influence on T-cell function in vivo.
Under the influence of imuthiol, T-cell precursors are induced
to differentiate, natural killer cell cytolytic activity is
increased, proliferative responses to mitogens are heightened,
and interleukin-2 production is increased. 3 " 12 Imuthiol has
been shown to speed the shift from immunoglobulin M production
to immunoglobulin G in response to a foreign antigen; this
change is considered to be T-cell mediated. 13 - 14
Immunosuppressed individuals regained normal T-cell function
after being treated with imuthiol 10 and when imuthiol was
administered to pregnant mice, T-cell dependent responses in
the offspring were enhanced along with neonatal growth rates;
27
birth rates remained unaf fected. 15 - 1S Toxicity studies have
shown imuthiol to be nonmutagenic, noncarcinogenic,
nonpyrogenic, and nonantigenic. 14 * 17 The immune-stimulating
properties of imuthiol suggested to us that this compound
might be an effective immunotherapeutic agent in weanling
pigs. Therefore, the objective of the present study was to
evaluate the influence of imuthiol on in vivo and in vitro
immune parameters in weaned pigs.
Materials and Methods
Animals and experimental design -- Twenty-one crossbred, 3-
week-old (6.5 kg) pigs were weaned and assigned to one of
three treatment groups (7 pigs per treatment) on the first day
of the experiment (day 0). Pigs from the same litter were
allotted to each treatment group. All pigs received a single
subcutaneous injection on day 0, of either: imuthiol at 25
mg/kg body weight; imuthiol at 2.5 mg/kg body weight; or
sterile physiologic saline. Pigs were housed by treatment
groups in 1.2 m x 1.5 m raised pens with plastic-coated
expanded-metal floors throughout the 19 days of the
experiment. Feed and water were provided ad libitum; ambient
temperature was maintained at 35C.
Lymphocyte transformation assay -- Lymphocyte
transformation assays were performed with a procedure similar
to that described by Blecha et al. 7 on days 0,3,6,9, and 18 of
the experiment. Briefly, heparinized whole blood, obtained by
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jugular venipuncture, was centrifuged (10 min at 700 x g) to
allow collection of the white blood cell layer. The buffy
coat was diluted with an equal volume of medium (Dulbecco's
Modified Eagle Medium3 , 25 mM HEPES*3 , 100 U/ml penicillin*,
100 ug/ml streptomycin3 , 250 ug/1 amphotericin-!}3 , 50 ug/ml
gentamicinc
,
essential and nonessential amino acids and
vitamins 3 ), layered onto 4 ml of a density gradient
(Histopaque 1077 13 ) , and subsequently centrifuged for 40 min at
950 x g. The cells at the medium-Histopaque interface were
collected, mixed with medium, and again layered over
Histopaque, then centrifuged for 30 min at 700 x g. The cells
were collected from the interface and washed three times in
medium, with the final wash in medium plus 10% (v/v) fetal
bovine serum** (FBS). Triplicate assays, with three mitogens
and medium controls, were performed in U-bottom microtiter
plates e using 2 x 10 5 cells/well in a 200 ul final volume of
medium + 10% FBS. Mitogens were used at the following
concentrations: concanavalin Af (Con A) 20 ug/ml,
phytohemagglutinin3 (PHA) 100 ul/ml, and pokeweed mitogen3
(PWM) 100 ul/ml. Cultures were incubated for 48 hours in a
93% air, 7% C0 2 humidified atmosphere at 37C, then pulsed with
1 uCi/well of [3H] -thymidine and incubated for an additional
18 hours, before being harvested onto glass-fiber discs.
After liquid scintillation counting, results were reported as
the mean counts per minute of triplicate assays.
Interleukin-2 assay -- Interleukin-2 determinations were
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performed in conjunction with the lymphocyte transformation
assays on days 0,3,6,9, and 18. Isolated lymphocytes (2 x 10 6
cells) were incubated in a 93% air, 7% C0 2 , humidified
atmosphere at 37C in 2 ml of medium +10% FBS containing 10
ug/ml Con A. After 24 hours, supernatants were harvested and
frozen (-20C) until assayed. Interleukin-2 was measured using
the IL-2 dependent cell line, CTL-FD. 1S • 19 Briefly, 2 x 10 5
washed CTL-FD cells were added to a series of 5 twofold serial
dilutions of supernatant in medium plus a medium control (RPMI
1640 a , 5 x 10~ 5 M 2-mercaptoethanol 13 , 5% v/v FBSd , 100 U/ml
penicillin^, 100 ug/ml streptomycin^) . Cultures were
incubated for 48 hours, pulsed with 1 uCi/well of
[
3H] thymidine, incubated for an additional 12 hours, and
harvested onto glass-fiber discs for liquid scintillation
counting. Data were analyzed using a logit data analysis
program with all samples being compared to an inhouse
standard. 2 °
Delayed-type hypersensitivity -- Phytohemagglutinin-
induced, delayed-type, hypersensitivity (DTH) tests were
performed on days 7 and 14 of the experiment.
Phytohemagglutinin*3 (250 ug) in 0.5 ml sterile saline was
injected intradermally in the skin fold of the flank. Skin-
fold thickness was measured 24 hours later, using a constant-
pressure dial micrometer. 7
Growth performance -- Pigs were individually weighed on
days 0,7,14, and 18 of the experiment; feed weights were
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determined on the same days on a per pen basis (pigs within a
treatment were housed in the same pen) . Average daily gain
and average daily feed intake were calculated, using the
totals for each housing unit.
Statistical analysis -- Data were analyzed as a randomized
complete block design by the General Linear Models Procedure
of the Statistical Analysis System. 21
Results
Lymphocyte blastogenesis and IL-2 production -- Lymphocyte
proliferative responses of medium controls for all treatments
were not different on any of the assay days (Table 1); this
uniformity suggests that imuthiol is not mitogenic in vivo in
pigs, however, in mitogen-stimulated cultures (day 9 with Con
A, day 3 with PHA, and days 3 and 6 with PWM) , one or both of
the imuthiol-treated groups had a significantly lower degree
of proliferation than the control animals. This pattern was
much more obvious when the data were pooled over all days of
the experiment (Fig. 1). When the lymphocyte proliferation
data were averaged over all sampling days, Con A- and PWM-
stimulated cultures from 2 5 mg/kg imuthiol-treated animals had
lower (P<0.05) proliferation than controls. Lymphocytes frcr.
25 mg/kg imuthiol-treated pigs also tended to have a lower
proliferative response to PHA than controls. In all cases,
2.5 mg/kg imuthiol-treated pigs were not significantly
different from either control or the 25 mg/kg imuthiol group.
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Interleukin-2 production, among the three treatment groups,
did not vary (P<0.05) on any single day; however, when pooled
over all sampling days (Fig. 2) a pattern similar to that of
the lymphocyte proliferation data was observed. Both
imuthiol-treated groups had lower (P<0.05) IL-2 production
when compared to control values.
Delayed-type hypersensitivity -- The delayed-type
hypersensitivity test results showed some divergence from the
above pattern (Table 2). On both test days, the 2.5 mg/kg
imuthiol-treated animals had a significantly lowered response
to PHA injection than the cor..rols. However, on day 14,
animals receiving the 25 mg/kg dose of imuthiol showed a
greater (P<0.05) response than the control group.
Growth performance -- Feed intake data were similar to both
the proliferation and IL-2 results (Table 3); imuthiol
treatment lowered the response. The data show a stepwise
progression, with the control animals consuming the most feed,
followed by the 2.5 mg/kg imuthiol-treated animals, and the 25
mg/kg imuthiol group consuming the least amount of feed.
Average daily gain values paralleled the feed intake data
numerically but were not statistically different.
Discussion /
These data evaluating the use of imuthiol in pigs are the
first of which we are aware. Most of the current literature
suggests that imuthiol causes an increase in both lymphocyte
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blastogenesis and IL-2 production in mice and humans 8-11 - 14 ;
however, stimulation of lymphocyte blastogenesis has been
reported to be delayed or to follow an initial period of
suppression. 14 Our data support previous reports 13 - 14 that
imuthiol has no, or a slightly inhibitory, effect on PWM-
induced blastogenesis. Additionally, imuthiol treatment in 3-
week-old pigs depressed IL-2 production and Con A-induced
lymphocyte blastogenesis. The feed intake data and average
daily gain both reflect an increasingly negative response to
increased imuthiol dosage. The results of the PHA-induced,
delayed-type, hypersensitivity test are more difficult to
interpret. Imuthiol has been reported to increase delayed-
type, hypersensitivity responses in mice. 10 - 13 In support of
this observation, the high-dose animals exhibited an increased
DTH response over control animals on day 14, yet on both test
days, the low-dose animals had the lowest DTH response.
Collectively, these results suggest several possibilities.
Perhaps the dose or route of administration for imuthiol
treatment that we used was incorrect. Even though these
factors were consistent with published data for mice and
humans 9 ' 11 - 13 ' 14 ' 1 *- 22 - 23
, different species often differ
widely in the correct dosage for a given drug. Another
possibility for the lack of an immunostimulatory effect by
imuthiol in pigs may be that the parameters we evaluated were
not adequate measure of the efficacy of imuthiol; perhaps an
evaluation of T-cell subsets and/or natural killer cell
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activity would have been more revealing. However, a final
consideration, especially in light of the growth performance
data, is that imuthiol may not be immunoenhancing in the
weanling pig. Further study will enable a better
understanding of the immunoregulating properties of imuthiol
in the pig.
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Table 1. Mitogen-stimulated lymphocyte blastogenesis in
3-week-old pigs administered imuthiol.
Control
Imuthiol
Day 2.5 nig/kg 25 mg/kg SEM
Concanavalin A
249.3 222.0274.6 20.9
3 311.0 265.7 278.6 42.8
6 335.8 345.6 278.1 32.8
9 395.9a 373. 4ab 328.3b 22.7
18 330.4 314.6 219.4 46.8
Phytohemagglutinin
572.8 617.1 537.0 48.1
3 623.7a 505.9b 584. lab 27.7
6 606.3 619.0 465.9 76.2
9 539.5 613.1 484.7 52.7
18 476.1 481.7
Pokeweed Mitogen
305.6 55.2
210.0 214.7 154.2 34.8
3 267.6a 194.1b 150.4b 20.9
6 245.4a 208.5a 138.0b 34.6
9 214.1 222.7 173.3 24.0
18 193.0
8.1
186.2
Control
112.1 40.3
8.9 11.1 1.4
3 9.9 10.5 8.7 1.8
6 5.4 4.6 7.5 1.1
9 21.0 16.3 17.2 2.4
18 20.2 17.9 16.2 3.4
ab Means within the same row with different superscripts
differ (P<0.05). Values are least squares means, cpm x 10
Pigs were injected sc with imuthiol on day 0.
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Table 2. Phytohemagglutinin skin-test reactions in 3-
week-old pigs administered imuthiol.
Control
Imuthiol
Day 2 . 5 mg/kg 25 mg/kg SEM
7
14
7.4 a
4.9 a
6.3 to
4.3 b
7.8 a
5.6 C
.35
.14
atooMeans within the same row with different super-
scripts differ (P<0.05). Values are least squares
means, mm. Pigs were injected sc with imuthiol on
day 0.
4 o
Table 3. Average daily gain (ADG) and average daily
feed intake (ADFI) in 3-week-old pigs administered
imuthiol.
Imuthiol
Item Control 2.5 mg/kg 25 mg/kg SEM
ADG, kg
ADFI, kg
.31
.45 s
24
.3,5*
23
.31'
0.6
0.01
at>Means within the same row with different super-
scripts differ (P<0.05).
4 1
Figure Legends
Fig. 1. The effect of imuthiol on mitogen-stimulated
lymphocyte proliferation. Bars represent data
that are pooled over the 5 sampling days of
the experiment. Bars with different super-
scripts differ (P<0.05).
O = Control 223= 2.5 mg/kg imuthiol
JH = 25 mg/kg imuthiol
Fig. 2. The effect of imuthiol on IL-2 production.
Bars represent data that are pooled over
the 5 sampling days of the experiment.
Bars with different superscripts differ
(P<0.05) .
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SUMMARY
Pseudorabies is a porcine herpesvirus of major importance in
the swine industry. Isoprinosine is an immunomodulating drug
that has been shown to be beneficial in treating herpesvirus
infections. Twenty-four, 7-week-old pigs were allotted within
litters to one of four groups: control (CONT), isoprinosine
(ISO), pseudorabies virus (PRV), or isoprinosine and
pseudorabies (ISO-PRV). Isoprinosine was administered daily
for 16 days (75 mg/kg/day, orally). Pigs were challenged with
pseudorabies virus (10" 5 TCID50) on day 4. Rectal
temperatures and viral excretion were monitored daily; total
and differential leukocyte counts, lymphocyte response to
mitogens, and interleukin-2 production were monitored every 4
days. Pigs challenged with pseudorabies virus became very
ill, with the ISO-PRV group most severely affected. Rectal
temperatures were elevated (P < 0.05) in virally challenged
pigs on days 5 to 12 and 14 to 16; isoprinosine did not alter
this effect. Pseudorabies virus-infected pigs displayed a
leukocytosis (P < 0.05) on days 12 and 16, primarily caused by
a neutrophilia. Concanavalin-A-stimulated lymphocyte
proliferation was decreased (P < 0.06) in both PRV and ISO-PRV
groups on day 12 compared to control animals, but only in the
PRV group on day 16. Pokeweed mitogen-stimulated lymphocyte
proliferation was decreased (P < 0.02) in ISO-PRV pigs on day
8. Interleukin-2 concentrations, pooled over all sampling
days, were decreased (P < 0.03) in pseudorabies virus-infected
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pigs. Viral excretion was not altered by isoprinosine
treatment. These data suggest that pseudorabies virus
infection decreased lymphocyte proliferative responses and
IL-2 production in pigs, and that isoprinosine did not
mitigate these effects.
INTRODUCTION
Pseudorabies, a porcine herpesvirus, is a major disease
of swine, annually causing losses of millions of dollars for
United States swine producers. 1 A recent review of
pseudorabies vaccines indicates a need for new, more effective
vaccines to aid in controlling this disease, most probably
exploiting subunit technology. 2 Another disease intervention
modality currently receiving attention is the use of
immunomodulators. For example, Pirtle et al. 3 1986, reported
that the effects of pseudorabies virus infection in young pigs
were mitigated by feeding butylated hydroxytoluene.
Isoprinosine is another drug that has shown some
immunoenhancing activity. First investigated for its
antiviral activity in 1972 by Gordon and Brown 4 , isoprinosine
was later found to act primarily through stimulation of the
immune system. 5 Subsequent research has shown that
isoprinosine is effective in restoring immune function in
several immunosuppressive conditions and is also beneficial in
the treatment of herpesvirus infections in humans
.
e
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Previous research in our laboratory has shown isoprinosine to
4 8
be immunoenhancing when administered in vivo to artifically
reared piglets. 8 In this experiment, we sought to evaluate
the effect of isoprinosine in pseudorabies virus-infected,
feeder pigs on the clinical course of disease as well as
various immune parameters.
MATERIALS AND METHODS
Animals and Experimental Design -- Isoprinosine and
pseudorabies virus (PRV) were applied as treatments to 24, 7-
week-old, crossbred pigs (10.7 kg + 2.3 sd obtained from a
PRV-free herd) with a 2x2 factorial arrangement of treatments
in a randomized, complete block, experimental design. Pigs
from the same litter were blocked across the four treatment
groups: control, isoprinosine (ISO), pseudorabies virus (PRV),
and isoprinosine and pseudorabies virus (ISO-PRV). Each
treatment group of six pigs was housed in a single room within
the Animal Health Research Facility of the Department of
Veterinary Science, University of Nebraska, Lincoln. Animals
were placed in their respective isolation rooms 1 week before
the experiment began to allow them to adjust to the new
environment
.
Isoprinosine (a gift from Newport Pharmaceuticals
International, Inc. Newport Beach, CA) was administered orally
once a day to the ISO and ISO-PRV groups throughout the
experiment (beginning on day ) at a rate of 75 mg/kg body
weight/day in a distilled water solution of 100 mg/ml. The
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remaining 12 pigs received daily doses of water in a similar
manner. Pseudorabies virus challange was performed on day 4.
The PRV and ISO-PRV groups received 10 5 tissue culture,
infective dose 50 (TCID 50 ) units of Shope strain pseudorabies
virus in aerosol form (half intranasally , half
conjunctivally) . Rectal temperatures and clinical signs of
disease were evaluated daily throughout the experiment.
Lymphocyte transformation -- Lymphocyte transformation
assays were performed on days 0, 4, 8, 12, and 16 of the
experiment. Whole blood, collected into heparinized blood
collection tubes via jugular venipuncture, was centrifuged (10
min at 700 x g) to allow collection of the white blood cell
layer. This buffy coat was added to 3 ml of medium (RPMI
1640 a , 100 U/ml penicillin, 3 100 ug/ml streptomycin, a 250 ug/1
amphotericin-B, a 50 ug/ml gentamicin,*3 ) then layered onto 4 ml
of a density gradient solution (Histopaque 1077, c ), and
subsequently centrifuged for 40 min at 950 x g. The cells at
the medium-Histopaque interface were collected, mixed with
medium, and again layered on Histopaque for a second
centrifugation of 30 min at 700 x g. Cells were collected
from the interface and washed three times in medium, with the
final wash in medium containing 10% (v/v) fetal bovine serum
(FBS, Hybri-sure,"1 ) . Triplicate assays, with three mitogens
and medium controls, were performed in U-bottom microtiter
plates'3 using 2 x 10 s cells/well in a 200 ul final volume of
medium + 10% FBS. Mitogens were used at the following final
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concentrations: concanavalin A f (Con A) 20 ug/ml,
phytohemagglutinin3 (PHA) 100 ul/ml, and pokeweed mitogen3
(PWM) lOOul/ml. Assay cultures were incubated for 48 hours in
a 93% air, 7% C02 , humidified atmosphere at 37 C. Cultures
were then pulsed with 1 uCi/well of [ 3H] -thymidine'3 (6.7
Ci/mmole) and incubated for an additional 18 hours before
being harvested onto glass-fiber discs. After liquid
scintillation counting, results were reported as the mean
counts per minute of triplicate assays.
Interleukin-2 assay -- Interleukin 2 (IL-2)
determinations were performed together with the lymphocyte
transformation assays on days 0, 4, 8, 12, and 16. Isolated
lymphocytes (2 x 10 6 cells from the above procedure) were
incubated in 24-well plates with 2 ml of medium + 10% FBS
containing 10 ug/ml Con A for 24 hours in a 37 C, 93% air, 7%
CO 2, humidified atmosphere. Supernatants then were collected
and frozen (-20 C) until assayed. Interleukin-2 was measured
using the IL-2 dependant cell line, CTL-FD. 9 ' 10 Assays were
conducted by adding 2.5 x 10 s washed CTL-FD cells to a series
of 5, twofold serial dilutions of supernatant in medium plus
one medium control (RPMI 1640, a ; 5 x 10" -5 M
2-mercaptoethanol,°; 5% v/v FBS; 100 U/ml penicillin; 100
ug/ml streptomycin)
. Cultures were incubated for for 48
hours, pulsed with 1 uCi/well of [ 3H] -thymidine, incubated a
final 12 hours, and harvested onto glass-fiber discs for
liquid scintillation counting. Logit analysis was performed
5 1
on the raw data, comparing all samples to an in-house
standard. 11
Total and differential leukocyte counts -- Blood samples
in sodium EDTA also were obtained on days 0, 4, 8, 12, and 16
to determine total leukocyte counts and differentials.
Leukocyte counts were performed using an electronic particle
counter. 11 Differential counts were performed on Wrights'
stained blood smears.
Pseudorabies virus titers -- Pseudorabies virus serum
neutralization titers were performed in the manner described
by Hill et al. 12
Nasal virus shedding -- Nasal swabs were obtained on a
daily basis from all pigs. Swabs were frozen at -70 C until
assayed by a cytopathic effect assay on vero monkey kidney
cells. 12 Titers were determined using the Reed and Muench
method. 13
Statistical Analysis -- The data were analyzed as a
randomized complete block design, blocking on litter, using
the General Linear Models procedure of Statistical Analysis
System. 14 Mean separations were performed by protected least
significant differences comparisons.
RESULTS
Pigs challenged with pseudorabies had severe clinical
symptoms. All pigs challenged exhibited signs consistent with
a pseudorabies virus infection, including: depression,
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anorexia, conjunctivitis, and dyspnea. Additionally, some
animals demonstrated central nervous system signs of ataxia
and head tilt, and the more severely affected animals died.
Animals receiving both virus and isoprinosine were clinically
more severely affected than those that received virus alone.
Four of six animals died in the ISO-PRV group, whereas only
one of six died in the group receiving virus alone (Fig 1).
All animals that were not challenged with virus remained
clinically normal throughout the experiment. Rectal
temperatures were elevated (P < 0.05) from day 5 through day
16 (excluding day 13; Fig 1) in animals that received virus.
Isoprinosine treatment did not affect rectal temperature in
either infected or noninfected groups.
Pseudorabies challenge was associated with an absolute
increase in total leukocytes (Fig 2). This increase was due
primarily to a marked increase in circulating neutrophils (Fig
3). Lymphocyte numbers showed an initial drop at 4 days post-
infection but rebounded 4 days later to above initial values
(Fig. 4). Overall, the ISO-PRV and PRV groups had similar
leukocyte responses (except for neutrophil levels on day 12
post-infection)
,
whereas both the ISO and control groups
maintained a steady baseline level. Isoprinosine treatment
did not appear to have an effect on leukocyte numbers either
in the presence or absence of viral challange.
Lymphocyte blastogenic responses to Con A (Fig 5) were
initially the same for all treatment groups. Pigs receiving
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isoprinosine did not differ from control animals throughout
the experiment. However, suppression of lymphocyte
blastogenesis was associated with pseudorabies virus challange
(P < 0.06 on days 8 and 12 postinfection for PRV animals, day
8 for ISO-PRV animals). Isoprinosine may have reversed the
lowered Con A-induced lymphocyte proliferative responses on
day 12; however, only two animals were alive in the ISO-PRV
group by 8 days postinfection. Lymphocyte blastogenesis
induced by PHA (Fig 5) was similar to the pattern observed
with Con A, and significant differences were not found. The
ISO and control groups did not differ greatly; a decreasing
proliferative response in the PRV and ISO-PRV groups was
present following viral challange, yet again at 12 days
postinfection, the ISO-PRV group returned to near control
values of proliferation. Lymphocyte blastogenesis with PWM
showed little change associated with isoprinosine treatment
(Fig 5). However, at 4 days postinfection, a decrease (P<
0.02) in PWM-induced lymphocyte proliferation occurred in the
ISO-PRV group. After this initial drop, PWM-induced
proliferative responses in the ISO-PRV group returned to near
control levels. The PRV group had numerically decreased
proliferation on all assay days post-infection.
Interleukin-2 levels did not differ significantly on any
sample day; however, some interesting observations were made
when the pooled data were analyzed (Table 1). Interleukin-2
production was significantly decreased (P < 0.03) in all
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animals receiving viral challenge compared to animals not
being challenged. Isoprinosine treatment did not alter
interleukin-2 production. Data for individual treatment
groups numerically reflect the viral associated suppression
but have no significant differences.
Serum neutralization titers were less than 1:2 in all
animals on the day of viral challange. At 12 days post-
infection, all animals not receiving virus maintained a titer
of less than 1:2, whereas those animals that did receive virus
had titers ranging from >1:4 to >1:32.
Nasal viral shedding was not affected by isoprinosine
treatment. No virus was detected from challenge control
animals. The group-average viral shedding did not differ
significantly between the PRV and ISO-PRV groups on any sample
day.
DISCUSSION
Viral-induced immunosuppression has been reported for
both bovine and human herpesvirus infections. 7 ' 15 Necrosis of
lymphoid tissue has been described subsequent to PRV infection
in pigs. 1 - 16 Additionally, Lee et al. 16 , have reported a
greatly suppressed immune response to a Bordetella
bronchiseptica bacterin after recovery from PRV infection.
Our data also support viral-induced immunosuppression caused
by PRV infection.
Mitogen-stimulated lymphocyte blastogenesis was
5 5
consistently decreased after viral challenge. Additionally,
inter.leukin-2 production was also lower in the viral
challenged animals. Collectively, these data suggest a
decrease in lymphocyte function. Other investigators have
reported no change in blastogenesis values after PRV infection
in assays using the same mitogens, but there are several
reports of increases in blastogenesis after infection when PRV
antigens were used as the stimulants. 17-19 This may suggest a
general suppression of T cell function within the framework of
a specific immune response to the infective agent. Recent
data have indicated that PRV may decrease lymphocyte
proliferative responses by inhibiting the monocyte-macrophage
system. i ' 2 ° A decrease in macrophage function may be
responsible for lowered T-helper function (e.g., by decreasing
IL-1 production) , which would decrease IL-2 production and
cause a concomitant drop in proliferation. Further work is
needed to examine these possibilities.
The neutrophilia and initial drop in circulating
lymphocytes that we observed would be expected responses to a
viral infection with subsequent tissue damage. Similarly,
serum neutralization titers indicate a susceptible population
of animals with subsequent seroconversion in pigs that were
infected. The viral shedding data (not shown) were
unremarkable; no differences were associated with isoprinosine
administration.
Isoprinosine has been shown to increase lymphocyte
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proliferative responses, increase IL-2 production, and alter
the clinical course of a herpesvirus infection when
administered in vivo to laboratory animals and humans. The
data from our experiment do not reflect these previous
observations. Overall, isoprinosine administration did not
have any marked effects on the paramaters observed in either
infected or noninfected animals. Our observation that Con
A-induced blastogenesis in the ISO-PRV group returned to
control levels on day 12 postinfection after initial
suppression should be judged critically. Animals in the
ISO-PRV group were more severely affected by the disease than
those in the PRV group, and 4 animals had died by 8 days
postinfection. Therefore, the data for the final 2 assay days
were based on only two animals in the ISO-PRV group: a small
sample from which to make inferences. Similar scrutiny should
be applied to the data from the other two mitogens.
There is evidence that the effects of pseudorabies virus
infection can be altered in the pig 3
,
however, we were unable
to discern any benefits from isoprinosine administration to
feeder pigs. Additionally, the observations of decreased
lymphocyte blastogenesis and decreased IL-2 production
support the conclusion that suppression of cell-mediated
immunity occurs during pseudorabies virus infections.
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Table 1. Mean IL-2 production. Data pooled from all assay-
days.
Statistical grouping
Treatment
PRV ISO IL-2/ml
Viral challenge effects
(pooled data)
1.61
2.27*
Isoprinosine effects
(pooled data)
1.83
2.05
Individual treatment
groups
+
+
+
2.37
2.17
1.74
1.49
* = P < 0.05
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FIGURE LEGENDS
Fig 1 - Mean rectal temperatures for all treatment groups, and
a plot of mortality in PRV challenged animals.
Fig 2 - Mean total leukocyte numbers for all treatment
groups.
Fig 3 - Mean neutrophil counts for all treatment groups.
Fig 4 - Mean lymphocyte counts for all treatment groups.
Fig 5 - Lymphocyte blastogenesis values (group means) as a
percent of the control group mean on individual assay days. (
* = P < 0.05) .
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FUTURE RESEARCH
The area of immune-modulators will continue to be a
growing and exciting area of research for years to come. The
work in the field must proceed along two lines simultaneously.
As newly discovered immunoactive substances become available
they should be screened for their effectiveness and possible
clinical use. Secondly, the mechanisms of immune regulation,
immune function, and immune dysfunction should be pursued so
that the "hows" and "whys" of immunomodulation will become
clear. This two pronged approach seems to be the most
efficient; allowing the clinical use of immunomodulators as
they become available while using those same substances and
other methods to further illucidate the molecular interactions
of the immune system.
I feel the most significant conclusion to be drawn from
my research is that PRV is immunosuppressive. Pseudorabies
virus infection may prove to be a good immunosuppression model
to further evaluate other influences on the immune system. As
usual further work is needed, for our knowledge is only
partial.
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Immunomodulators are becoming the focus of a large group
of researchers today. The possibility of manipulating the
immune system to further understand its regulation and to
treat or prevent disease poses an almost irresistable lure.
Many types of immunomodulators have been described and tested,
and much of the information concerning immunomodulators in
swine is discussed. In addition, two experiments involving
the use of immunomodulators in young pigs are presented.
I. Sodium diethyldithiocarbamate (imuthiol) is an
immunoactive drug that has been shown to be an effective T
cell stimulant. Consequently, mitogen-stimulated lymphocyte
proliferation, delayed-type hypersensitivity (DTH) reactions,
interleukin-2 (IL-2) production, and growth performance were
evaluated in 3-week-old pigs treated with imuthiol.
Lymphocyte proliferative responses to Con A and PWM were
reduced (P<0.05) in pigs treated with imuthiol at 25 mg/kg;
PHA proliferative responses were not influenced by imuthiol
treatment. Imuthiol at 2.5 mg/kg and 25 mg/kg lowered IL-2
production when compared to saline-treated controls.
Delayed-type hypersensitivity responses to PHA were higher in
25 mg/kg imuthiol-treated pigs; however, 2.5 mg/kg imuthiol-
treated pigs had lower DTH reactions. Imuthiol at 2.5 mg/kg
and 25 mg/kg reduced (P<0.05) average daily feed intake.
These data suggest that in vivo imuthiol treatment in pigs
lowers lymphocyte proliferative responses, IL-2 production,
and growth performance.
II. Pseudorabies is a porcine herpesvirus of major
importance in the swine industry. Isoprinosine is an
immunomodulating drug that has been shown to be beneficial in
treating herpesvirus infections. Twenty-four, 7-week-old pigs
were allotted within litters to one of four groups: control
(CONT), isoprinosine (ISO), pseudorabies virus (PRV), or
isoprinosine and pseudorabies (ISO-PRV). Isoprinosine was
administered daily for 16 days (75 mg/kg/day, orally). Pigs
were challenged with pseudorabies virus (10 s TCID 50) on day
4. Rectal temperatures and viral excretion were monitored
daily; total and differential leukocyte counts, lymphocyte
response to mitogens, and interleukin-2 production were
monitored every 4 days. Pigs challenged with pseudorabies
virus became very ill, with the ISO-PRV group most severely
affected. Rectal temperatures were elevated (P < 0.05) in
virally challenged pigs on days 5 to 12 and 14 to 16;
isoprinosine did not alter this effect. Pseudorabies
virus-infected pigs displayed a leukocytosis (P < 0.05) on
days 12 and 16, primarily caused by a neutorphilia.
Concanavalin-A-stimulated lymphocyte proliferation was
decreased (P < 0.06) in both PRV and ISO-PRV groups on day 12
compared to control animals, but only in the PRV group on day
16. Pokeweed mitogen-stimulated lymphocyte proliferation was
decreased (P < 0.02) in ISO-PRV pigs on day 8. Interleukin-2
concentrations, pooled over all sampling days, were decreased
(P < 0.03) in pseudorabies virus-infected pigs. Viral
excretion was not altered by isoprinosine treatment. These
data suggest that pseudorabies virus infection decreased
lymphocyte proliferative responses and IL-2 production in
pigs, and that isoprinosine did not mitigate these effects.
